To investigate changes in the Apparent Diffusion Coefficient (ADC) using diffusion-weighted imaging (DWI) in men on active surveillance for prostate cancer taking dutasteride 0.5 mg or placebo.
We analysed 37 men, randomised to 6 months of daily dutasteride (n = 18) or placebo (n = 19), undergoing 3T multi-parametric Magnetic Resonance Imaging (mpMRI) scans at baseline and 6 months. Images were reviewed blind to treatment allocation and clinical information. Mean ADC of peripheral (PZ) and transition (TZ) zones, and MR-suspicious lesions were compared between groups over 6 months. Conspicuity was defined as the PZ divided by tumour ADC, and its change over 6 months was assessed.
A decrease in mean conspicuity in the dutasteride group (but not the controls) was seen over 6 months (1.54 vs 1.38; p = 0.025). Absolute changes in ADC and conspicuity were significantly different between placebo and dutasteride groups at 6 months: (-0.03 vs 0.08, p = 0.033) and (0.11 vs -0.16, p = 0.012), as were percentage changes in the same parameters: (-2.27% vs 8.56% p = 0.048) and (9.25% vs -9.89% p = 0.013).
Dutasteride was associated with increased tumour ADC and reduced conspicuity. A lower threshold for triggering biopsy might be considered in men on dutasteride undergoing mpMRI for prostate cancer.
• Dutasteride increases ADC and reduces conspicuity in small mpMRI-visible prostate cancers. • Knowledge of dutasteride exposure is important in the interpretation of prostate mpMRI. • A lower threshold for triggering biopsy may be appropriate on dutasteride.
European radiology. 2017 May 18 [Epub ahead of print]
Francesco Giganti, Caroline M Moore, Nicola L Robertson, Neil McCartan, Charles Jameson, Simon R J Bott, Mathias Winkler, Giulio Gambarota, Brandon Whitcher, Ramiro Castro, Mark Emberton, Clare Allen, Alex Kirkham
Department of Radiology, University College London Hospital NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK. ., Division of Surgery & Interventional Science, University College London, London, UK., Department of Pathology, University College London Hospital NHS Foundation Trust, London, UK., Department of Urology, Frimley Park Hospital, Surrey, UK., Department of Urology, Charing Cross Hospital, Imperial College NHS Trust, London, UK., INSERM, U1099, Rennes, F-35000, France., Klarismo, London, UK., Research and Development, GlaxoSmithKline, Philadelphia, PA, USA., Department of Radiology, University College London Hospital NHS Foundation Trust, 235 Euston Road, London, NW1 2BU, UK.